MersV1, PubMed, Checkpoint, bibRecord, 000033

Type 1 interferons as a potential treatment against COVID-19.

Identifieur interne : 000033 ( PubMed/Checkpoint ); précédent : 000032; suivant : 000034

Type 1 interferons as a potential treatment against COVID-19.

Auteurs : Erwan Sallard [France] ; François-Xavier Lescure [France] ; Yazdan Yazdanpanah [France] ; France Mentre [France] ; Nathan Peiffer-Smadja [France]

Source :

Antiviral research [ 1872-9096 ] ; 2020.

RBID : pubmed:32275914

Abstract

Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.

DOI: 10.1016/j.antiviral.2020.104791
PubMed: 32275914

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000053
to stream PubMed, to step Curation: 000053

Links to Exploration step

pubmed:32275914

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Type 1 interferons as a potential treatment against COVID-19.</title>
<author><name sortKey="Sallard, Erwan" sort="Sallard, Erwan" uniqKey="Sallard E" first="Erwan" last="Sallard">Erwan Sallard</name>
<affiliation wicri:level="3"><nlm:affiliation>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name>
<affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name>
<affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentre">France Mentre</name>
<affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name>
<affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32275914</idno>
<idno type="pmid">32275914</idno>
<idno type="doi">10.1016/j.antiviral.2020.104791</idno>
<idno type="wicri:Area/PubMed/Corpus">000053</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000053</idno>
<idno type="wicri:Area/PubMed/Curation">000053</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000053</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000033</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000033</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Type 1 interferons as a potential treatment against COVID-19.</title>
<author><name sortKey="Sallard, Erwan" sort="Sallard, Erwan" uniqKey="Sallard E" first="Erwan" last="Sallard">Erwan Sallard</name>
<affiliation wicri:level="3"><nlm:affiliation>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name>
<affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name>
<affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentre">France Mentre</name>
<affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name>
<affiliation wicri:level="3"><nlm:affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Antiviral research</title>
<idno type="eISSN">1872-9096</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32275914</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>178</Volume>
<PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>07</Day>
</PubDate>
</JournalIssue>
<Title>Antiviral research</Title>
<ISOAbbreviation>Antiviral Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Type 1 interferons as a potential treatment against COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>104791</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0166-3542(20)30205-9</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2020.104791</ELocationID>
<Abstract><AbstractText>Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the potential activity of type 1 interferons on SARS-CoV-2, and the relevance of evaluating these molecules in clinical trials for the treatment of COVID-19.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sallard</LastName>
<ForeName>Erwan</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>École Normale Supérieure de Paris, 45 Rue D'Ulm, 75005, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lescure</LastName>
<ForeName>François-Xavier</ForeName>
<Initials>FX</Initials>
<AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yazdanpanah</LastName>
<ForeName>Yazdan</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mentre</LastName>
<ForeName>France</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Peiffer-Smadja</LastName>
<ForeName>Nathan</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Université de Paris, IAME, INSERM, F-75018, Paris, France; Department of Infectious and Tropical Diseases, Assistance Publique - Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, 75018, Paris, France. Electronic address: nathan.peiffer-smadja@inserm.fr.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Antiviral Res</MedlineTA>
<NlmUniqueID>8109699</NlmUniqueID>
<ISSNLinking>0166-3542</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Interferon</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
</KeywordList>
<CoiStatement>Declaration of competing interest None.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32275914</ArticleId>
<ArticleId IdType="pii">S0166-3542(20)30205-9</ArticleId>
<ArticleId IdType="doi">10.1016/j.antiviral.2020.104791</ArticleId>
<ArticleId IdType="pmc">PMC7138382</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Sallard, Erwan" sort="Sallard, Erwan" uniqKey="Sallard E" first="Erwan" last="Sallard">Erwan Sallard</name>
</region>
<name sortKey="Lescure, Francois Xavier" sort="Lescure, Francois Xavier" uniqKey="Lescure F" first="François-Xavier" last="Lescure">François-Xavier Lescure</name>
<name sortKey="Mentre, France" sort="Mentre, France" uniqKey="Mentre F" first="France" last="Mentre">France Mentre</name>
<name sortKey="Peiffer Smadja, Nathan" sort="Peiffer Smadja, Nathan" uniqKey="Peiffer Smadja N" first="Nathan" last="Peiffer-Smadja">Nathan Peiffer-Smadja</name>
<name sortKey="Yazdanpanah, Yazdan" sort="Yazdanpanah, Yazdan" uniqKey="Yazdanpanah Y" first="Yazdan" last="Yazdanpanah">Yazdan Yazdanpanah</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000033 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000033 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:32275914
   |texte=   Type 1 interferons as a potential treatment against COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:32275914" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Type 1 interferons as a potential treatment against COVID-19.

Type 1 interferons as a potential treatment against COVID-19.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki